Previous studies have demonstrated that PD-1 inhibitors are effective in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC). However, whether the combination of PD-1 inhibitors and antiangiogenic agents benefit advanced NSCLC patients as subsequent therapy remains unknown. In this study, we retrospectively reviewed the efficacy and safety profile of this combination strategy as subsequent therapy for NSCLC patients in a real-world setting.

中文翻译：

---

结合程序性细胞死亡-1 (PD-1) 抑制剂和抗血管生成靶向剂作为晚期或转移性非小细胞肺癌 (NSCLC) 后续治疗的疗效和安全性

既往研究表明，PD-1抑制剂可有效治疗晚期或转移性非小细胞肺癌（NSCLC）。然而，PD-1 抑制剂和抗血管生成药物的组合作为后续治疗是否有益于晚期 NSCLC 患者仍然未知。在本研究中，我们回顾性地回顾了这种联合策略在现实环境中作为 NSCLC 患者后续治疗的疗效和安全性。